Currently, the only available direct renin inhibitor for the treatment of hypertension is Aliskiren, which is an orally active non-peptide drug with high selectivity.529–531 However, it did not achieve satisfying effects in clinical trail.242 And another drug, ACT‐077825, lacks evidence to confirm its effect. Here, REN is linked to hypertensive disorder.